

TABLE OF CONTENTS

1.0	MATERIALS SUPPLIED	1
2.0	MATERIALS REQUIRED, BUT NOT SUPPLIED	2
2.1	Optional Equipment and Materials	2
3.0	CELL CULTURE CONDITIONS	3
3.1	Media Required	3
3.2	Methods Used	3
4.0	ASSAY PROCEDURE	4
4.1	Controls	4
4.2	Cell Stimulation and Assay Plate Setup	5
4.3	Substrate Loading	6
4.4	Incubation	6
4.5	Detection	7
5.0	DATA ANALYSIS	7
5.1	Background Subtraction	7
5.2	Response Ratio Calculations	8
5.3	Visual Observation of Intracellular LiveBLazer™ FRET B/G Substrate (CCF4-AM)	8
6.0	PURCHASER NOTIFICATION	9

1.0 MATERIALS SUPPLIED

Description:	This cell line utilizes GeneBLazer® beta-lactamase technology. CellSensor™ NFAT- <i>bla</i> HEK 293T cells contain a beta-lactamase reporter gene under control of the nuclear factor of activated T cells (NFAT) response element stably integrated into HEK 293T cells. This cell line can be used to detect agonists and/or antagonists of the NFAT signaling pathway, or as a parental cell line to build specific G-protein coupled receptor (GPCR) assays after transfection of additional genes of interest. NFAT- <i>bla</i> HEK 293T cells have been shown to respond to PMA + thapsigargin.
Cat. no.:	K1179
Shipping Condition:	Dry ice
Storage Condition:	Liquid nitrogen. Immediately upon receipt, cells must be stored in liquid nitrogen. Cells cannot be stored at -80°C, as they will quickly lose viability.
Quantity:	~2,000,000 cells (2 × 10 ⁶ cells/mL)
Cell Line Name:	NFAT- <i>bla</i> HEK 293T
Application:	This cell line can be used to detect agonists/antagonists of the NFAT signaling pathway or as a parental cell line to build specific G-protein coupled receptor (GPCR) assays after transfection of additional genes of interest.
Growth Properties:	Adherent
Cell Phenotype:	Epithelial
Selection Marker:	Zeocin™ (200 µg/mL)
Vector Used:	pcDNA 3XNFAT- <i>bla</i> -zeo vector
Response Element Sequence:	GGAGGAAAACTGTTTCATACAGAAAGGCGT 1 forward, 2 reverse
Mycoplasma Testing:	Negative
Biosafety Level:	2

For Research Use Only. Not for use in diagnostic procedures.

2.0 MATERIALS REQUIRED, BUT NOT SUPPLIED

Media/Reagents	Recommended Source	Cat. no.
LiveBLazer™ Loading Kit containing: LiveBLazer™ FRET B/G Substrate (CCF4-AM) substrate (5 mg) DMSO for Solution A Solution B Solution C	Life Technologies	K1030*
Cell Culture Freezing Medium	Life Technologies	11101-011
DMEM (high-glucose)	Life Technologies	11965-092
DMSO	Fluka	41647
Fetal bovine serum, (FBS), dialyzed, tissue-culture grade (DO NOT SUBSTITUTE)	Life Technologies	26400-044
Non-essential amino acids (NEAA)	Life Technologies	11140-050
Penicillin/Streptomycin	Life Technologies	15140-122
Phosphate-buffered saline without calcium and magnesium [PBS]	Life Technologies	14190-136
HEPES (1 M, pH 7.3)	Life Technologies	15630-080
Sodium pyruvate	Life Technologies	11360-070
Phorbol 12-myristate 13-acetate (PMA)	Sigma	P8139
Thapsigargin	Sigma	T9033
0.05% Trypsin/EDTA	Life Technologies	25300-054
Zeocin™ antibiotic	Life Technologies	R250-01

* Other sizes or Loading Kits containing CCF2-AM are available.

Consumables	Recommended Source	Cat. no.
Black-wall, clear-bottom, 384-well assay plates (with low fluorescence background)	Costar	3712
Compressed air	Various	—
Conical tubes, 15 mL, sterile	Various	—
Internally threaded cryogenic vials, 1.8 mL	Various	—
Tissue culture flasks	Various	—

Equipment	Recommended Source
Class II biological safety cabinet	Various
Dual wave-length bottom-reading fluorescence plate reader	Various
Filters (see Sections 4.5.1 and 5.3)	Chroma Technologies
Hemocytometer (or another cell counting method)	Various
Humidified 37°C/5% CO ₂ incubator	Various
Inverted microscope (with phase contrast capabilities)	Various
Liquid nitrogen tank	Various

2.1 Optional Equipment and Materials

- Epifluorescence or fluorescence-equipped microscope, equipped with appropriate filters
- Microplate centrifuge

3.0 CELL CULTURE CONDITIONS

3.1 Media Required

Component	Growth Medium (+)	Growth Medium (-)/Assay Medium
DMEM	90%	90%
Dialyzed FBS	10%	10%
NEAA	0.1 mM	0.1 mM
Sodium pyruvate	1 mM	1 mM
HEPES (pH 7.3)	25 mM	25 mM
Penicillin	100 U/mL	100 U/mL
Streptomycin	100 µg/mL	100 µg/mL
Zeocin™	200 µg/mL	—

Note: Unless otherwise stated, all media and solutions should be at least room temperature (37°C is best) before adding them to the cells.

3.2 Methods Used

Follow these methods exactly, as they have been validated specifically for optimal performance of this cell line. At first opportunity, create and store an aliquot of cells for back-up.

3.2.1 Thawing Method

- Place 14 mL of Growth Medium (-) into a T75 flask.
- Place the flask in a 37°C/5% CO₂ incubator for 15 minutes to allow medium to equilibrate to the proper pH and temperature.
- Remove vial of cells to be thawed from liquid nitrogen and rapidly thaw by placing in a 37°C water bath with gentle agitation for 1–2 minutes. Do not submerge vial in water.
- Decontaminate the vial by wiping with 70% ethanol before opening in a Class II biological safety cabinet.
- Transfer the vial contents dropwise into 10 mL of Growth Medium in a sterile 15 mL conical tube.
- Centrifuge cells at 200 × g for 5 minutes.
- Aspirate supernatant and resuspend the cell pellet in 1 mL of fresh Growth Medium (-).
- Transfer contents to the T75 tissue culture flask containing pre-equilibrated Growth Medium (-) and place flask in the 37°C/5% CO₂ incubator.
- At first passage switch to Growth Medium (+).

3.2.2 Propagation Method

- Cells should be passaged or fed at least twice a week. Cells should be maintained between 10% and 90% confluence. Do not allow cells to reach confluence.
- To passage cells, aspirate medium, rinse once in PBS, add Trypsin/EDTA (3 mL for a T75 flask, 5 mL for a T175 flask, and 8 mL for T225 flask) and swirl to coat the cells evenly. Cells usually detach after ~2–5 minutes exposure to Trypsin/EDTA. Add an equal volume of growth medium to inactivate trypsin.
- Verify under a microscope that cells have detached and clumps have completely dispersed.
- Spin down cells and resuspend in Growth Medium.

3.2.3 Freezing Method

- Harvest the cells as described in **Section 3.2.2**, Step 2. After detachment, count the cells, then spin cells down and resuspend in 4°C Cell Culture Freezing Medium at 2 × 10⁶ cells/mL.
- Dispense 1.0 mL aliquots into cryogenic vials.
- Place in an insulated container for slow cooling and store overnight at -80°C.
- Transfer to liquid nitrogen the next day for storage.

4.0 ASSAY PROCEDURE

The following instructions outline the recommended procedure for determining activity of compounds as modulators (agonists or antagonists) of the NFAT signaling pathway using beta-lactamase as the readout.

4.1 Controls

Plate layouts and experimental outlines will vary; in screening mode, we recommend using at least five wells for each control: Unstimulated Control, Stimulated Control, and Cell-Free Control.

Note: Certain solvents may affect assay performance. The effect of a test compound solvent should be assessed prior to screening. The cell stimulation described below is carried out in the presence of 0.5% DMSO to simulate the effect that the test compound solvent may have on the assay. If other solvents and/or solvent concentrations are used, the following assay should be changed accordingly.

Data point	Agonist Assay	Antagonist Assay	Purpose of Data Point
Unstimulated Control Wells	1. 32 μ L cells diluted in Assay Medium 2. 4 μ L 5% DMSO stock solution 3. 4 μ L Assay Medium	1. 32 μ L cells diluted in Assay Medium 2. 4 μ L 5% DMSO stock solution 3. 4 μ L Assay Medium	Provides the Unstimulated Emission Ratio, which is a portion of the Response Ratio. Unstimulated Emission Ratio = (Unstimulated 460 nm/ Unstimulated 530 nm). See Section 5.0 (Data Analysis).
Stimulated Control Wells	1. 32 μ L cells diluted in Assay Medium 2. 4 μ L 5% DMSO stock solution 3. 4 μ L 10X stock solution of PMA + Thapsigargin	1. 32 μ L cells diluted in Assay Medium 2. 4 μ L 5% DMSO stock solution 3. 4 μ L 10X stock solution of PMA + Thapsigargin	Provides the Stimulated Emission Ratio, which is a portion of the Response Ratio. Stimulated Emission Ratio = (Stimulated 460 nm/ Stimulated 530 nm). See Section 5.0 (Data Analysis).
Cell-Free Control Wells	1. 36 μ L Assay Medium 2. 4 μ L 5% DMSO stock solution	1. 36 μ L Assay Medium 2. 4 μ L 5% DMSO stock solution	Provides the background blue and green emission values to be subtracted from both unstimulated and stimulated blue and green emission values to yield the net unstimulated and stimulated blue and green emission values.
Test Compound Wells	1. 32 μ L cells diluted in Assay Medium 2. 4 μ L 10X stock of test compounds in 5% DMSO 3. 4 μ L Assay Medium	1. 32 μ L cells diluted in Assay Medium 2. 4 μ L 10X stock of test compounds in 5% DMSO 3. 4 μ L 10X stock solution of PMA + Thapsigargin	Provides the experimental data on whether or not a test compound is active as an agonist or antagonist in the assay.

4.2 Cell Stimulation and Assay Plate Setup

4.2.1 Precautions

1. Work on a dust-free, clean surface. Always handle the 384-well, black-wall, clear-bottom assay plate by the sides; do not touch the clear bottom of the assay plate.
2. If pipetting manually, it may be necessary to centrifuge the plate briefly at room temperature (for 1 minute at $14 \times g$) after additions to ensure all the assay components are on the bottom of the wells.

4.2.2 Plating Cells (Day 1)

1. Harvest cells from culture in Growth Medium as described in **Section 3.2.2**, Step 2 and resuspend in Assay Medium at a density of 156,250 cells/mL.
2. Add 36 μ L per well of the Assay Medium to the Cell-Free Control wells. Add 32 μ L (5,000 cells) per well of the cell suspension to the Test Compound wells, the Unstimulated Control wells, and Stimulated Control wells.

Note: Cells should be plated one day prior to cell stimulation.

4.2.3 Preparation of Stock Solution (Day 2)

1. Prepare a stock solution of 5% DMSO.
2. Prepare a 10X stock of test compounds in 5% DMSO.
3. Prepare a 10X stock of PMA + Thapsigargin in assay media. For an antagonist screen, use ~5 nM PMA + 2 nM Thapsigargin final concentration or EC_{80} (10X = 50 nM PMA, 20 nM Thapsigargin). For an agonist screen, use ~5 nM PMA + 3 nM Thapsigargin final concentration or max stim (10X = 50 nM PMA, 30 nM Thapsigargin). We recommend running a dose response curve to determine the EC_{80} for your 10X PMA + Thapsigargin solution.

4.2.4 Agonist Assay Plate Setup

Note: This subsection provides directions for performing an agonist assay. Directions for performing an antagonist assay can be found in **Section 4.2.5**.

1. Add 4 μ L of the stock solution of 5% DMSO to the Unstimulated Control wells, the Stimulated Control wells, and to the Cell-Free Control wells.
2. Add 4 μ L of Assay Medium to the Test Compound and Unstimulated Control wells.
3. Add 4 μ L of the 10X stock solution of PMA + Thapsigargin to Stimulated Control wells.
4. Add 4 μ L of the 10X stock of test compounds to the Test Compound wells.
5. Incubate the agonist assay plate in a humidified 37°C/5% CO₂ incubator for 5 hours.

4.2.5 Antagonist Assay Plate Setup

Note: This subsection provides directions for performing an antagonist assay. Directions for performing an agonist assay are provided in **Section 4.2.4**.

1. Add 4 μ L of the 10X stock of test compounds to the Test Compound wells.
2. Add 4 μ L of the stock solution of 5% DMSO to the Stimulated Control wells, the Unstimulated Control wells, and the Cell-Free Control wells.
3. If desired, incubate the test compounds with the cells at 37°C/5% CO₂ before proceeding. Typically, a one-hour incubation is sufficient.
4. Add 4 μ L of the 10X stock solution of PMA + Thapsigargin to the Test Compound wells and the Stimulated Control wells.
5. Add 4 μ L of Assay Medium to the Unstimulated Control wells.
6. Incubate the antagonist assay plate in a humidified 37°C/5% CO₂ incubator for 5 hours.

4.3 Substrate Loading

Preparation of 6X CCF2-AM or LiveBLAzer™ FRET B/G Substrate (CCF4-AM) Loading Solution and cell loading should be done in the absence of direct strong lighting. Turn off the light in the hood.

4.3.1 LiveBLAzer™ FRET B/G Substrate (CCF4-AM) or CCF2-AM Loading Protocol

This protocol is designed for loading cells with LiveBLAzer™ FRET B/G Substrate (CCF4-AM) or CCF2-AM, using the following solutions. The protocol below references only LiveBLAzer™ FRET B/G (CCF4-AM). CCF2-AM can be substituted for LiveBLAzer™ FRET B/G (CCF4-AM).

Reagents	Storage and Handling
LiveBLAzer™ FRET B/G Substrate (CCF4-AM)	The product is supplied as a dried powder. The molecular weight of CCF2-AM is 1082 g/mol; the molecular weight of LiveBLAzer™ FRET B/G Substrate (CCF4-AM) is 1096 g/mol. Store the product at -20°C, desiccated and protected from light.
Dry DMSO	Used to dissolve LiveBLAzer™ FRET B/G Substrate (CCF4-AM) for preparation of Solution A.
Solution A	LiveBLAzer™ FRET B/G Substrate (CCF4-AM) stock solution; 1 mM LiveBLAzer™ FRET B/G Substrate in dry DMSO. Prepare a 1 mM LiveBLAzer™ FRET B/G Substrate stock solution in dry DMSO. Store the LiveBLAzer™ FRET B/G Substrate stock solution at -20°C, desiccated and protected from light. Before each use, let frozen stock solution warm to room temperature and remove desired amount of reagent. Immediately recap the vial after each use to reduce moisture uptake and return to -20°C storage. Stored under these conditions, Solution A is stable for approximately three months. Once thawed, Solution A may appear slightly yellow. This is normal.
Solution B	Store the reagent at room temperature (18–22°C) protected from direct light. Under cold lab conditions [colder than 18°C (65°F)], the solution may freeze or a white precipitate may form. In this case, warm and mix the solution (~35°C) until thawed and the precipitate dissolves. Mix thoroughly before use.
Solution C	Keep tightly closed and store in a cool, dry place. Store the reagent at room temperature (18–22°C) protected from direct light.

4.3.2 Preparation of 6X LiveBLAzer™ FRET B/G Substrate (CCF4-AM) Loading Solution

1. Add 6 µL of Solution A to 60 µL of Solution B and vortex.
2. Add 934 µL Solution C to the combined solutions from Step 1 with vortexing.

4.3.3 Cell Loading

1. Remove assay plate from incubator and allow it to equilibrate to room temperature prior to loading.
2. Add 8 µL of the 6X Loading Buffer to each well (C_i of LiveBLAzer™ FRET B/G (CCF4-AM) = 1 µM).

4.4 Incubation

1. Cover the plate to protect it from light and evaporation.
 2. Incubate at room temperature for 120 minutes.
- Note:** Handle the plate gently and do not touch the bottom.

4.5 Detection

All measurements are made at room temperature from the bottom of the wells, preferably in 384-well, black-wall, clear-bottom assay plates with low fluorescence background. Before reading the plate, remove dust from the bottom with compressed air.

Note: Some plates/fluorescence plate readers experience edge effects, which may affect data. If edge effects are noticed, plate layout should be considered when setting up the assay.

4.5.1 Instrumentation, Filters, and Plates

- Almost all dual wavelength, bottom read fluorescence plate readers can be used to detect beta-lactamase using LiveBLAzer™ FRET B/G (CCF4-AM) or CCF2-AM.

Note: If you are uncertain of whether your instrument can be used for this assay, please contact Technical Support for assistance.

- Filters for fluorescence plate reader:

For ratiometric readout using a fluorescence plate reader:

Excitation filter: 409/20 nm

Emission filter: 460/40 nm

Emission filter: 530/30 nm

4.5.2 Reading an Assay Plate

- Set the fluorescence plate reader to bottom-read mode.
- Allow the lamp in the fluorescence plate reader to warm up for at least 10 min. before making measurements.
- Use the following filter selections:

	Read 1	Read 2
Purpose:	Measure fluorescence in the blue channel	Measure fluorescence in the green channel
Excitation filter:	409/20 nm	409/20 nm
Emission filter:	460/40 nm (using the gain determined during calibration)	530/30 nm (using the gain determined during calibration)

Typically, set the fluorescence plate reader to 5 reads/well.

5.0 DATA ANALYSIS

5.1 Background Subtraction

Background subtraction for both channels (460 nm and 530 nm) is essential to obtain meaningful data. This can be accomplished either automatically using software connected to the fluorescence plate reader, or manually after each assay plate has been read.

Use the assay plate layout to identify the location of the Cell-Free Control wells. These control wells are used for background subtraction.

5.1.1 Automatic Background Subtraction

Use the assay plate layout to designate appropriate Cell-Free Control wells and enable background subtraction for both sets of emission scans.

5.1.2 Manual Background Subtraction

1. Determine the average emission from the Cell-Free Control wells at both 460 nm (Average Em_{460} Background) and 530 nm (Average Em_{530} Background).
2. Calculate the Net Stimulated Em_{460} and Em_{530} values and the Net Unstimulated Em_{460} and Em_{530} values, as shown below:

Stimulated Cells

Net Stimulated Em_{460} = Em_{460} of stimulated sample – Average Em_{460} Background

Net Stimulated Em_{530} = Em_{530} of stimulated sample – Average Em_{530} Background

Unstimulated Cells

Net Unstimulated Em_{460} = Em_{460} of unstimulated sample – Average Em_{460} Background

Net Unstimulated Em_{530} = Em_{530} of unstimulated sample – Average Em_{530} Background

5.2 Response Ratio Calculations

1. Calculate the Stimulated Emission Ratio for each well, as shown below.

$$\text{Stimulated Emission Ratio} = \frac{\text{Net Stimulated } Em_{460}}{\text{Net Stimulated } Em_{530}}$$

2. Calculate the Unstimulated Emission Ratio for each well, as shown below.

$$\text{Unstimulated Emission Ratio} = \frac{\text{Net Unstimulated } Em_{460}}{\text{Net Unstimulated } Em_{530}}$$

3. Calculate the Mean Unstimulated Emission Ratio for each assay plate, as shown below.

$$\text{Mean Unstimulated Emission Ratio} = \frac{\text{Sum of Unstimulated Emission Ratios}}{\text{Total Number of Wells Containing Unstimulated Cells}}$$

4. Calculate the Response Ratio for each well of interest, as shown below.

$$\text{Response Ratio} = \frac{\text{Stimulated Emission Ratio } (Em_{460}/Em_{530})}{\text{Mean Unstimulated Emission Ratio } (Em_{460}/Em_{530})}$$

Note: All Response Ratios are calculated using the Mean Unstimulated Emission Ratio. The Response Ratio determined with 5nM PMA + 3nM Thapsigargin and LiveBLazer™ FRET B/G Substrate (CCF4-AM) was 6–8.

5.3 Visual Observation of Intracellular LiveBLazer™ FRET B/G Substrate (CCF4-AM)

Note: Microscopic visualization of cells will cause photobleaching. Always read the assay plate in the fluorescence plate reader before performing microscopic visualization.

An inverted microscope equipped for epifluorescence and either a xenon or mercury excitation lamp are typically required to view the LiveBLazer™ FRET B/G Substrate (CCF4-AM) signal in cells. To inspect the cells, a long-pass filter passing blue and green fluorescence light is needed so that you can visually identify whether the cells are fluorescing green or blue.

Recommended filter sets for observing beta-lactamase activity are described below and are available from Chroma Technologies (800-824-7662).

Chroma Set # 41031

Excitation filter: HQ405/20x (405 ±10)

Dichroic mirror: 425 DCXR

Emission filter: HQ435LP (435 long-pass)

Filter sizes vary for specific microscopes and need to be specified when the filters are ordered. For epifluorescence microscopes, a long-pass dichroic mirror is needed to separate excitation and emission light and should be matched to the excitation filter (to maximally block the excitation light around 405 nm, yet allow good transmission of the emitted light).

6.0 PURCHASER NOTIFICATION

Limited Product Warranty

Life Technologies Corporation and/or its affiliate(s) warrant their products as set forth in the Life Technologies' General Terms and Conditions of Sale found on Life Technologies' website at www.lifetechnologies.com/termsandconditions. If you have any questions, please contact Life Technologies at www.lifetechnologies.com/support.

Limited Use Label License: Research Use Only

The purchase of this product conveys to the purchaser the limited, non-transferable right to use the purchased amount of the product only to perform internal research for the sole benefit of the purchaser. No right to resell this product or any of its components is conveyed expressly, by implication, or by estoppel. This product is for internal research purposes only and is not for use in commercial applications of any kind, including, without limitation, quality control and commercial services such as reporting the results of purchaser's activities for a fee or other form of consideration. For information on obtaining additional rights, please contact outlicensing@lifetech.com or Out Licensing, Life Technologies, 5791 Van Allen Way, Carlsbad, California 92008.

Limited Use Label License No. 108: Lentiviral Technology

Notice to Purchaser: The Lentiviral Technology (based upon the lentikat™ system) is licensed from Cell Genesys, Inc., and corresponding patents and applications in other countries for internal research purposes only. Use of this technology for gene therapy applications or bioprocessing other than for non-human research use requires a license from Cell Genesys (Cell Genesys, Inc. 342 Lakeside Drive, Foster City, California 94404). The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity), including non-gene therapy research and target validation applications in laboratory animals.

Limited Use Label License No. 317: LentiVector® Technology

Notice to Purchaser: This product is licensed from Oxford BioMedica Ltd., Oxford, UK, and is provided for use in academic and commercial in vitro and in vivo research for elucidating gene function, and for validating potential gene products and pathways for drug discovery and development but excludes any use of LentiVector® technology for: creating transgenic birds for the purpose of producing useful or valuable proteins in the eggs of such transgenic birds, the delivery of gene therapies, and for commercial production of therapeutic, diagnostic or other commercial products not intended for research use where such products do not consist of or incorporate a lentiviral vector. Information about licenses for commercial uses excluded under this license is available from Oxford BioMedica, Ltd., Medawar Centre, Oxford Science Park, Oxford OX4 4GA UK enquiries@oxfordbiomedica.co.uk or BioMedica Inc 11622 El Camino Real #100, San Diego CA 92130-2049, USA. LentiVector is a registered U.S. and European Community trade mark of Oxford BioMedica plc.

Limited Use Label License No. 445: GeneBLAzer® Technology

Notice to Purchaser: The right to use this product for internal research specifically excludes the right to use this product to identify, discover, and profile compounds that act as a flavor, fragrance or taste-enhancers and modify a target identified in taste, olfaction, or pheromone detection, which compound does not require FDA approval of an NDA for claims of safety and efficacy. The right to use methods claimed in the foregoing patents with this product for research purposes can only be acquired by the use of GeneBLAzer® substrates purchased from Life Technologies Corporation or its authorized distributors.

Use of Genetically Modified Organisms (GMO)

Information for European Customers. The NFAT-*bla* HEK 293T cell line(s) are genetically modified with the plasmid pcDNA 3XNFAT-*bla*-zeo vector. As a condition of sale, use of this product must be in accordance with all applicable local legislation and guidelines including EC Directive 90/219/EEC on the contained use of genetically modified organisms.

Disclaimer

LIFE TECHNOLOGIES CORPORATION AND/OR ITS AFFILIATE(S) DISCLAIM ALL WARRANTIES WITH RESPECT TO THIS DOCUMENT, EXPRESSED OR IMPLIED, INCLUDING BUT NOT LIMITED TO THOSE OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. TO THE EXTENT ALLOWED BY LAW, IN NO EVENT SHALL LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) BE LIABLE, WHETHER IN CONTRACT, TORT, WARRANTY, OR UNDER ANY STATUTE OR ON ANY OTHER BASIS FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING BUT NOT LIMITED TO THE USE THEREOF.

Trademarks

The trademarks mentioned herein are the property of Life Technologies Corporation and/or its affiliate(s) or their respective owners.

© 2013 Life Technologies Corporation. All rights reserved.